NO.1 Biotech adjusts BAT3306 development strategy
Biotech announced that after a careful evaluation of the company's drug supervision and management policies and other factors, it plans to adjust the development strategy of BAT3306 (pembrolizumab) and terminate the ongoing BAT3306-002 study on BAT3306 (an evaluation of the combination of BAT3306 and chemotherapy with Credesia) ® A multicenter, randomized, double-blind phase I/III study on the pharmacokinetics, efficacy, and safety of combination chemotherapy in patients with stage IV non-small cell lung cancer.
Comment: Biotech's adjustment of this research and development strategy is based on the fact that the necessity of efficacy comparison studies has greatly decreased when the European and American drug regulatory authorities approve the marketing application of biosimilar products. However, Biotech stated in the announcement that it will carefully evaluate and make a decision on whether to continue advancing the BAT3306 project in the future, reflecting the current fierce competition in the PD-1 track and the difficulties in the development of biosimilars.
NO.2 Tonghua Dongbao plans to transfer a portion of its shares in Tebao Biotechnology through an agreement
On the evening of May 22nd, Tonghua Dongbao announced that the company plans to transfer 23.1876 million shares of unrestricted tradable shares of Tebao Biotechnology through an agreement transfer, accounting for 5.7% of the current total share capital of Tebao Biotechnology. The transfer price is 56.12 yuan per share, and the total transfer price is 1.301 billion yuan. Tonghua Dongbao stated that the transfer of shares in Tebao Biotechnology is an overall arrangement made based on the long-term needs of Tonghua Dongbao's continuous deepening of innovation, transformation and development strategy.
Comment: As a leading insulin company, Tonghua Dongbao has faced pressure from centralized procurement in recent years. The funds withdrawn this time will increase the pipeline of innovative drugs such as GLP-1.
NO.3 Lizhu Group plans to acquire equity in Vietnam's IMP company
Lizhu Group announced that its wholly-owned overseas subsidiary LIAN SGP HOLDING PTE. LTD. plans to acquire 64.81% of the shares of Imexpharm Corporation (IMP), a Vietnamese listed company, held by SK Investment Vina III Pte. Ltd., Sunrise Kim Investment Joint Stock Company, and KBA Investment Joint Stock Company, for a purchase price of VND 57308.15 billion (approximately RMB 1.587 billion at the midpoint of the exchange rate on the day of the agreement signing).
Commentary: Lizhu Group stated in the announcement that IMP is a leading pharmaceutical enterprise in Vietnam, mainly engaged in the research and development, production, and sales of drugs. Its products mainly include antibiotics, cardiovascular and cerebrovascular drugs, etc., which have high synergy with the company's existing products. This acquisition will lay a solid foundation for Lizhu Group to further expand its overseas markets and support its long-term strategy of internationalization and sustainable development in the pharmaceutical industry.
NO.4 Gakos/Elis KRAS G12C inhibitor approved for market launch
According to the official website of the State Administration for Market Regulation, the KRAS G12C inhibitor Golirense, developed in collaboration with Elise, has been approved for marketing in China. It is used to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least first-line systemic treatment for KRAS G12C mutations.
Comment: Insight database shows that there are currently 31 KRAS G12C inhibitors in clinical development in China, and the competition is quite fierce. Yifang Biotech/Zhengda Tianqing's Gesolese and Jinfang Pharmaceutical/Xinda Biosciences' Fuzerese have been approved for market in China in the second half of 2024, with Golerese becoming the third domestic product after approval. Another 5 KRAS G12C inhibitors are currently in phase III clinical development.
Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before use. Based on this operation, the risk is borne by oneself.